American Board of Internal Medicine
Antivirals, Drug Resistance, Immunology, Infectious Disease, Influenza Virus, Viruses and Virology
BA Magna Cum Laude, Williams College
Certificate, Columbia University Post-Baccalaureate Premedical Program
MD with Distinction in Research, Mount Sinai School of Medicine
MD, Mount Sinai School of Medicine
Residency, Internal Medicine
Mount Sinai Hospital
Fellowship, Infectious Disease
Mount Sinai Hospital
Sir William Osler Young Investigator Award
Interurban Clinical Club
Alpha Omega Alpha
Lambda Chapter of New York, Mount Sinai School of Medicine
Special Citation for Fellows-in-Training
Oral Abstract Presentation, 47th Annual Meeting of the Infectious Diseases Society of America
Special recognition for outstanding abstracts submitted by fellows-in-training.
Distinction in Research
Mount Sinai School of Medicine
Recognition for original, peer-reviewed research performed in medical school by a candidate for the M.D. degree.
Phi Beta Kappa
Gamma Chapter of Massachusetts, Williams College
The Bouvier Lab studies host and viral factors that affect the respiratory transmission of influenza viruses.
For more information about our research interests, please visit the Bouvier lab website.
Rialdi A, Campisi L, Zhao N, Lagda AC, Pietzsch C, Ho JS, Martinez-Gil L, Fenouil R, Chen X, Edwards M, Metreveli G, Jordan S, Peralta Z, Munoz-Fontela C, Bouvier NM, Merad M, Jin J, Weirauch M, Heinz S, Benner C, van Bakel H, Basler C, García-Sastre A, Bukreyev A, Marazzi I. Topoisomerase 1 inhibition suppresses inflammatory genes and protects from death by inflammation. Science 2016 May; 352(6289): aad7993.
Bouvier NM. Cystic fibrosis and the war for iron at the host-pathogen battlefront. Proceedings of the National Academy of Sciences of the United States of America 2016 Feb 113(6):1480-1482.
Bouvier NM. Animal models for influenza virus transmission studies: a historical perspective [review]. Current opinion in virology 2015 Aug; 13: 101-108.
Varble A, Albrecht RA, Backes S, Crumiller M, Bouvier NM, Sachs D, García-Sastre A, tenOever BR. Influenza A virus transmission bottlenecks are defined by infection route and recipient host. Cell host & microbe 2014 Nov; 16(5): 691-700.
Lowen AC, Bouvier NM, Steel J. Transmission in the Guinea Pig Model [review]. Current topics in microbiology and immunology 2014 Jul;(385): 157-183.
Hai R, Schmolke M, Leyva-Grado VH, Thangavel RR, Margine I, Jaffe EL, Krammer F, Solórzano A, García-Sastre A, Palese P, Bouvier NM. Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility. Nature Communications 2013 Dec; 4: 2854.
Bouvier NM, Rahmat S, Pica N. Enhanced Mammalian Transmissibility of Seasonal Influenza A/H1N1 Viruses Encoding an Oseltamivir-Resistant Neuraminidase. Journal of virology 2012 Jul; 86(13): 7268-7279.
Bouvier NM. The science of security versus the security of science [editorial]. The Journal of infectious diseases 2012 Jun; 205(11): 1632-1635.
Thangavel RR, Bouvier NM. Animal models for influenza virus pathogenesis, transmission, and immunology [review]. Journal of Immunological Methods 2014; 410: 60-79.
Seibert CW, Rahmat S, Krammer F, Palese P, Bouvier NM. Efficient transmission of pandemic H1N1 influenza viruses with high-level oseltamivir resistance. Journal of virology 2012 May; 86(9): 5386-5389.
Pica N, Chou YY, Bouvier NM, Palese P. Transmission of influenza B viruses in the guinea pig. Journal of virology 2012 Apr; 86(8): 4279-87.
Pica N, Bouvier NM. Environmental factors affecting the transmission of respiratory viruses. Current opinion in virology 2012 Feb 2(1).
Bouvier NM, Lowen AC. Animal Models for Influenza Virus Pathogenesis and Transmission [review]. Viruses 2010; 2(8): 1530-1563.
Bouvier NM, Lowen AC, Palese P. Oseltamivir-resistant influenza A viruses are transmitted efficiently among guinea pigs by direct contact but not by aerosol. Journal of virology 2008 Oct; 82(20): 10052-10058.
Bouvier NM, Palese P. The biology of influenza viruses. Vaccine 2008 Sep; 26 Suppl 4: D49-53.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Bouvier did not report having any of the following types of financial relationships with industry during 2015 and/or 2016: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.